Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

FDA approval of Provention Bio’s Teplizumab could bring first disease-modifying therapy to type 1 diabetes space

If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes (T1D). Teplizumab is one of the first therapeutics to demonstrate a disease-modifying effect for T1D. As it is a prevention therapy, it is expected to encourage early screening […]
Read more

Biogen’s aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed

Following a controversial FDA Advisory Committee meeting for Biogen’s aducanumab for mild Alzheimer’s disease, where the panel members sharply recommended against approval, the therapy will likely face significant barriers to coverage if it gains an agency nod in March, according to reporting from William Newton, Pharma Writer for the Investigative News team at GlobalData, a […]
Read more

Global IPF market set to reach $3.6bn by 2029

The idiopathic pulmonary fibrosis (IPF) market was valued at $2.5bn in 2019 across the seven major markets (7MM*), and is expected to grow to $3.6bn by 2029 with a compound annual growth rate (CAGR) of 3.8%, according to GlobalData, a leading data and analytics company. According to the company’s latest report: ‘Idiopathic Pulmonary Fibrosis: Opportunity Analysis […]
Read more

Akebia’s vadadustat MACE profile remains unclear and US approval path in non-dialysis CKD anemia uncertain

Akebia Therapeutics presented additional data from its Phase III PRO2TECT trial at the 2020 American Society of Nephrology Kidney Week conference, that evaluated the efficacy and safety of vadadustat versus erythropoiesis stimulating agent (ESA) Aranesp (darbepoetin alfa) for the treatment of chronic kidney disease (CKD) anemia in adult non-dialysis patients. Despite the latest additional data, […]
Read more

Pharmaceutical industry continues to bet big on AI

Declining pharmaceutical research and development (R&D) efficiency has been an ongoing problem in pharmaceutical sector. With emerging technologies reshaping various business, pharma is looking to capitalize on artificial intelligence (AI) to streamline operating models and address R&D’s productivity challenges, says GlobalData, a leading data and analytics company. According to a survey as part of GlobalData’s latest report, Digital Transformation and […]
Read more

US, UK and Germany are top manufacturers for COVID-19 vaccines

Vaccine developers are selecting contract manufacturing organizations (CMOs) close to home for their COVID-19 vaccine, as the US, UK and Germany are the most popular supplier locations, says GlobalData, a leading data and analytics company. Johanna Swanson, MBA, Product Manager at GlobalData, comments: “These supply chains contrast with the general trend within the pharma industry to […]
Read more

The Italian acromegaly market will more than double in size by 2029, says GlobalData

Marketed therapeutics for the treatment of acromegaly generated sales of at least $33m in Italy in 2019. The value of this market is expected to more than double, surpassing $75m in 2029, according to GlobalData, a leading data and analytics company. GlobalData’s recently published report, ‘Acromegaly and Gigantism: Global Drug Forecast and Market Analysis to 2029’, reveals that the size of the Italian acromegaly market will increase at a 10-year compound annual growth rate (CAGR) of 8.6%. Magdalene Crabbe, Senior Pharmaceutical Analyst at GlobalData, comments: “The Italian market will experience rapid […]
Read more

BrainStorm’s NurOwn fails Phase III trial, demonstrating the struggle to develop effective ALS treatment

Following Brainstorm Cell Therapeutics announcement of topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy NurOwn; Sarah Elsayed, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view on the opportunities and challenges in this market: “NurOwn is the second pipeline drug to fail a clinical trial for ALS this year, […]
Read more

Kala Pharmaceuticals should focus on educating ophthalmologists and having a favorable price point for Eysuvis

The US Food and Drug Administration (FDA) recently announced the approval of Kala Pharmaceuticals’ Eysuvis, a topical steroid (0.25% loteprednol etabonate ophthalmic suspension), for short-term treatment of the signs and symptoms of dry eye syndrome (DES). In order to smoothen market access for this new therapy and facilitate its uptake, Kala Pharmaceuticals will need to […]
Read more

COVID-19 vaccine production driving contract service agreements for recombinant vector vaccines

COVID-19 is driving many small pharma companies that do not have the expertise or funds to run their own manufacturing facilities to outsource production. COVID-19 vaccine developers are signing contract service agreements at an unprecedented rate, as pharma companies have publicly revealed 42 contract manufacturing service agreements for 28 unique pipeline COVID-19 vaccines, as manufacturing companies […]
Read more

Growth of T2D market driven by increasing diagnosed prevalence of disease and emergence of novel pipeline agents

Type 2 diabetes (T2D) is a crowded and competitive landscape, with market growth primarily driven by an increasing diagnosed prevalent population across nine major markets (9MM*) and the emergence of novel pipeline agents, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Type 2 Diabetes: Global Drug Forecast and Market Analysis to 2029’, reveals […]
Read more
1 … 74 75 76 77 78 … 108